Literature DB >> 25913437

Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States.

Z G Jiang1,2, Y Tsugawa3,4, E B Tapper1,2, M Lai1,2, N Afdhal1,2, S C Robson1,2, K J Mukamal2,3.   

Abstract

BACKGROUND: Elevated fasting triglyceride is often associated with metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease. On the other hand, as liver disease progresses, patients may develop hepatocellular dysfunction that impairs triglyceride production. AIM: To test the hypothesis that lower fasting triglyceride levels may paradoxically indicate more advanced liver disease.
METHODS: A cross-sectional analysis of 11 947 adults aged 20 years or older without chronic viral hepatitis from the National Health and Nutrition Examination Survey 1999-2010 was performed to analyze the relationships between fasting triglyceride levels and five validated non-invasive indices of liver fibrosis, including Fibrosis 4 Score (FIB4), NAFLD Fibrosis Score (NFS), Ast-Platelet Ration Index, AST/ALT ratio and BARD.
RESULTS: Low-fasting triglyceride levels were consistently associated with elevated liver fibrosis indices. Individuals in the lowest quintile of triglycerides (TG) had an adjusted odds ratio (OR) of 3.0 (95% CI, 1.7-5.2; P < 0.001) for advanced fibrosis estimated by FIB4 score and OR of 1.8 (95% Cl, 1.2-2.7; P = 0.009) estimated by NFS, compared to individuals in the highest quintile. This association remained highly significant when restricted to individuals with abnormal LFTs from suspected NAFLD. This inverse relationship was continuous, and more pronounced among men and whites (P interaction <0.001 and 0.008 respectively), but not modified by age or body mass index. In addition, fasting TG had a stronger, more direct association with liver fibrosis indices than did albumin or total bilirubin.
CONCLUSIONS: Fasting triglyceride levels were inversely associated with liver fibrosis indicators in American adults, especially among white men. Our findings suggest that sequential lipid measurements may serve as a useful disease marker in the management of chronic liver disease patients.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25913437     DOI: 10.1111/apt.13216

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.

Authors:  Zhenghui G Jiang; Elliot B Tapper; Misung Kim; Margery A Connelly; Sarah A Krawczyk; Eric U Yee; Mark A Herman; Kenneth J Mukamal; Michelle Lai
Journal:  J Clin Gastroenterol       Date:  2018 May/Jun       Impact factor: 3.062

2.  Associations of insulin resistance, inflammation and liver synthetic function with very low-density lipoprotein: The Cardiovascular Health Study.

Authors:  Z Gordon Jiang; Ian H de Boer; Rachel H Mackey; Majken K Jensen; Michelle Lai; Simon C Robson; Russell Tracy; Lewis H Kuller; Kenneth J Mukamal
Journal:  Metabolism       Date:  2015-10-22       Impact factor: 8.694

3.  Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.

Authors:  Zhenghui G Jiang; Elliot B Tapper; Margery A Connelly; Carolina F M G Pimentel; Linda Feldbrügge; Misung Kim; Sarah Krawczyk; Nezam Afdhal; Simon C Robson; Mark A Herman; James D Otvos; Kenneth J Mukamal; Michelle Lai
Journal:  Liver Int       Date:  2016-02-24       Impact factor: 5.828

4.  Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome.

Authors:  Yu-Tsung Chou; Zih-Jie Sun; Wei-Chen Shen; Yi-Ching Yang; Feng-Hwa Lu; Chih-Jen Chang; Chung-Yi Li; Jin-Shang Wu
Journal:  Front Nutr       Date:  2022-02-11

5.  Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Jun-Hyuk Lee; Yu-Jin Kwon; Kyongmin Park; Hye Sun Lee; Hoon-Ki Park; Jee Hye Han; Sang Bong Ahn
Journal:  Nutrients       Date:  2022-07-24       Impact factor: 6.706

Review 6.  Metabolic-associated fatty liver disease and lipoprotein metabolism.

Authors:  Joerg Heeren; Ludger Scheja
Journal:  Mol Metab       Date:  2021-04-20       Impact factor: 7.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.